Table 3.

Combination Antibiotics for Methicillin Resistant Staphylococcus aureus-I Trial Desirability of Outcome Ranking Endpoint With Distribution by Treatment Group [10]

Combination Antibiotics for Methicillin Resistant Staphylococcus aureus-I Trial DOOR Endpoint			DOOR Distribution		Partial Credit Score
Rank	Alive	How Many of the Following: Treatment Failure Infectious Complications Grade 4 Adverse Events	Combination Therapy (n = 31)	Standard Therapy (n = 29)	Scenario A	Scenario B	Scenario C	Scenario D
1	Yes	0 of 3	15 (48%)	18 (62%)	100	100	100	100
2	Yes	1 of 3	11 (35%)	3 (10%)	100	0	100	75
3	Yes	2 of 3	0 (0%)	2 (7%)	100	0	0	50
4	Yes	3 of 3	0 (0%)	0 (0%)	100	0	0	25
5	No (death)	Any	5 (16%)	6 (21%)	0	0	0	0
			DOOR Results		Partial Credit Results
			Probability (95% CI) of a Higher DOOR Using Combination Therapy vs Standard Therapy		Estimated Between-treatment Partial Credit Difference a,b (95% CI)
					A	B	C	D
			0.47 (0.33, 0.60)		4.6 (–16, 25)	–13.7 (–40, 12)	11.5 (–10, 33)	1.7 (–18, 21)
					P = .74	P = .31	P = .35	P = .62

DOOR probability and partial credit scenarios are presented.

Abbreviations: CI, confidence interval; DOOR, desirability of outcome ranking.

^a Estimated between-treatment difference is equal to mean combination therapy score minus mean standard therapy score.

^b Exact Wilcoxon P values are presented for scenarios A through D. P values using t test ranged from 0.29 to 0.86.